Home Team humanoid robots to be deployed by mid-2027, $100m to be invested: Josephine Teo, Singapore News
SINGAPORE — Home Team officers will work together with their robot counterparts when the latter are deployed as soon as by mid-2027.
The humanoid robots will perform high-risk tasks such as firefighting, hazardous materials (hazmat) operations, and search-and-rescue missions.
Initially, the robots will be controlled remotely by human operators, but are expected to be powered by artificial intelligence (AI) and deployed autonomously from 2029.
During autonomous deployment, AI will allow the machines to respond to different scenarios, with humans supervising and intervening only when necessary.
On May 26, four of these robots, which are being developed by the Home Team Science and Technology Agency (HTX), were showcased at the opening of the AI TechXplore exhibition.
The two-day science and technology exhibition, held at Fusionopolis One, highlights HTX's efforts to leverage AI to enhance Home Team operations.
The exhibition was held alongside the HTX career fair, Careers@HTX.
Three of the robots on display are about 1.7m-tall, while the fourth is half a metre shorter.
HTX engineers built an exo-suit for operators to wear to control the smaller robot.
Information from the exo-suit is transmitted to the robot, allowing it to replicate the operator's movements in real time.
The operator also wears a virtual reality headset that allows him or her "to see" through the robot's cameras to perform various tasks.
The event also saw the launch of Phoenix, HTX's large language model (LLM) that was trained in-house and is familiar with the Singaporean and Home Team context, conversant in all four official languages in Singapore.
Phoenix will be the brain of the Home Team's AI capabilities.
Speaking at the event, Minister for Digital Development and Information Josephine Teo said $100m will be invested into the new Home Team Humanoid Robotics Centre (H2RC), which will be dedicated to developing humanoid robots intended for public safety.
It is the first such facility in the world, and is slated to become operational by mid-2026.
It will feature zones for data collection, AI model training and robotics development, and will house high-performance computing resources.
Teo said: "Criminals are exploiting technology in ways never before imagined. As a result, law enforcement agencies, too, must understand how the technologies are being misused.
"But that on its own is not going to be enough. We must also have the capabilities to use the technology to fight crime, to do better for our people."
The minister added that H2RC will push the frontiers of AI.
She said: "This initiative marks a fundamental shift in the development of robotics capabilities in the Home Team — from today's pre-programmed systems to tomorrow's Gen AI-powered intelligent platforms that can move, think, and act autonomously to protect and save lives."
Ang Chee Wee, Chief AI Officer and Assistant Chief Executive (Digital and Enterprise) at HTX, said the facility is a significant step forward for HTX's AI strategy, as advances in robotics open up new possibilities for frontline support.
He said: "By putting humanoid robots in realistic environments, we can evaluate how AI can complement our officers, enhance safety, and support the long-term operational needs of the Home Team."
The Home Team has used multiple robots over the years, with one of the earliest iterations of a patrol robot being used at large-scale events in 2018.
The pace of development and deployment quickened after the formation of HTX in end-2019, which helped develop the Rover-X robotic dog and the more recent cyborg cockroaches sent to Myanmar to assist in search-and-rescue efforts.
Drones are now also a common sight at large public events such as the recent political rallies, and help with both crowd control and other police operations.
The advent of humanoid robots looks set to further shape the security scene in Singapore, with security provider Certis announcing on May 19 that it too has received its first humanoid robot.
Dr Daniel Teo, director of Robotics, Automation and Unmanned Systems Centre of Expertise at HTX, said he was looking forward to further harnessing the potential of robots for the Home Team.
He said: "Public safety operations require robotic systems that are adaptable and resilient. These AI-driven robots have a huge potential to enhance the safety and effectiveness of frontline officers."
[[nid:718333]]
This article was first published in The Straits Times. Permission required for reproduction.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
a day ago
- Straits Times
Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong
Mirxes CEO Dr Zhou Lihan, his wife Yeap Su Phing, parents and two children at the Hong Kong Stock Exchange in Central after the Singapore biotech firm launched its IPO on May 23. PHOTO: MIRXES – Singapore has produced its first billion-dollar biotechnology start-up, 25 years after it began formally building its life sciences industry. Mirxes, which invented and produces the world's first blood test kit to detect early stage gastric cancer, is helmed by Dr Zhou Lihan, a naturalised Singaporean from the country's maiden batch of life sciences graduates. He arrived on the Lion City's shores as a wide-eyed 15-year-old PRC (People's Republic of China) scholar, navigating life and studies in a foreign country. Today, the 42-year-old is chief executive officer and co-founder of Mirxes (pronounced 'm'raek'sis'). It is the first South-east Asian biotech start-up to achieve a valuation of more than US$1 billion (S$1.29 billion), when on May 23 it launched its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX). The company's market capitalisation is HK$8.29 billion, or US$1.06 billion. It has been trading around HK$30 per share, up 28 per cent from its listing price of HK$23.30. It is also South-east Asia's first biotech firm to list on HKEX. The microRNA-based cancer-detection start-up, which was spun out of Singapore's public sector R&D agency A*Star in 2014, has yet to become a household name in the country. But it is already a big player in the regional biotech industry. Now, the company has reached a critical level in its development where it can build on its success only by leveraging on an expansive fund-raising platform with a mature base of investors familiar with the industry. That is why, instead of listing in Singapore, Mirxes opted to do so first in Hong Kong, Dr Zhou told The Straits Times. He does not, however, discount the possibility of Mirxes listing in Singapore eventually. Dr Zhou's life story in the Republic tracks closely with some of the country's strategic economic policies over the years. 'I left China in 1998 after learning, through the Suzhou-Singapore Industrial Park project, about the opportunity to take on a scholarship to come to Singapore,' the Suzhou-born Dr Zhou told ST in an unmistakably Singaporean accent. Dr Zhou (second from left) with his fellow PRC scholars studying in Singapore's Anglican High School in 1998. PHOTO: COURTESY OF ZHOU LIHAN The project was launched in 1994 for China to adapt the Republic's development experiences to its own context, and for Singapore to develop an external wing to its economy. The PRC scholarship system is a Singapore Government-sponsored scheme for top Chinese teenage students since the 1990s, aimed at having them eventually contribute to economic development and potentially set down roots in the country . Finding love at NUS After going through the local education system at Anglican High School and Temasek Junior College, Dr Zhou enrolled at the National University of Singapore (NUS) in 2003, among the first batch of life sciences students. The life sciences programme was introduced as part of a government initiative in 2000 to develop the Republic into a regional biomedical hub. 'Because I spent most of my formative years in Singapore, all my friends and family are in Singapore. I even met my wife in NUS on shuttle bus A2, heading from the arts faculty to (university hostel) Prince George's Park,' Dr Zhou recalled with a laugh. Dr Zhou (top row, second from left), with Associate Professor Too Heng-Phon (far right) and fellow researchers from Prof Too's lab during their university days in 2008. PHOTO: COURTESY OF ZHOU LIHAN His wife, a Malaysian-born Singaporean, was an NUS arts student whom he got to know better in the students' union , he explained. They have a son and a daughter, aged eight and three, respectively. The family, including Dr Zhou's parents who have also moved from Suzhou to Singapore , were at HKEX in the central business district to witness Mirxes' IPO launch on May 23. Mirxes' history dates back to Dr Zhou's days at NUS, where he obtained his PhD in biochemistry and molecular biology at the Yong Loo Lin School of Medicine in 2012. During his PhD studies, he, fellow scientist Zou Ruiyang and their mentor, Associate Professor Too Heng-Phon, developed the technology to detect microRNA (micro ribonucleic acid), the smallest genetic material ever found in living things. Dr Zhou with his mentor, Prof Too, on his graduation day in 2007. PHOTO: COURTESY OF ZHOU LIHAN Their research, which the trio took with them to A*Star when they joined the agency in 2010, proved so ground-breaking that they set up an enterprise three years later with the agency's support and a government grant to commercialise their technology. Thus, Mirxes was born: a three-person start-up with Dr Zhou as CEO, Dr Zou as chief technology officer, and Prof Too as chief scientific adviser, aimed at developing an accurate, affordable and easily accessible early detection system for various cancers and other diseases. In the decade since, Mirxes has grown into a 350-strong company with a presence in China, Japan, Malaysia, the Philippines and the United States, and partnerships with global biotech giants including Johnson & Johnson and Pfizer. Dr Zhou (left) and Mirxes' co-founder, Dr Zou Ruiyang, at the biotech startup in the initial years after it spun off from A*Star. PHOTO: MIRXES The firm's flagship invention, GastroClear, in 2019 became the world's first molecular blood test approved for early detection of gastric cancer in high-risk populations. It was developed in close collaboration with the Singapore Gastric Cancer Consortium. The test – available in Singapore for less than $150 at public hospitals or around $250 in private clinics – is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. GastroClear has an 87 per cent accuracy, better than any other blood-based tests for the detection of gastric cancer. Patients who test positive are recommended to undergo an endoscopy for more specific results. The test is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. PHOTO: NATIONAL UNIVERSITY HEALTH SYSTEM Listing in Hong Kong Months of careful consideration preceded Mirxes' decision to list in Hong Kong over Singapore. Ultimately, it came down to two key factors. 'Firstly, our flagship product GastroClear is focused on stomach cancer, a very Asian disease,' Dr Zhou said. 'China alone accounts for half of all stomach cancer cases worldwide.' The Hong Kong platform provides a gateway into mainland China, the biggest market not just for stomach cancer tests, but also for the scale and speed of cancer clinical trials to accelerate the firm's research and development efforts. 'So listing in (the Chinese territory of) Hong Kong makes sense, because the investors here will understand our product's value to them.' Secondly, he added, HKEX's dedicated biotech listing regime has built up an investor base that 'understands how to look at biotech firms' financials without getting scared off'. Mirxes is still in the red, reporting net losses exceeding US$92 million for 2024 – 30 per cent more than the previous year. It is already generating revenue, although the US$20 million it reported for 2024 is a 16 per cent drop from that in 2023. 'People get worried that Mirxes is losing money,' Dr Zhou said. 'But if we want to be competitive globally, we have to invest in R&D and innovation. But that's something that our South-east Asian investor base is not yet familiar with.' HKEX's investors, on the other hand, are no strangers to promising yet still-loss-making start-ups. Hong Kong in 2018 started allowing yet-to-be-profitable biotech firms to list on its main board under the exchange's Chapter 18A regulations, to attract companies in cutting-edge industries. Since then, more than 70 such firms – which would otherwise not have qualified to list – have launched their IPOs in the city, gaining access to much-needed funds to grow their fledgling technologies and innovations . Mirxes CEO Dr Zhou Lihan (right) with a Hong Kong Stock Exchange representative at the IPO ceremony in Hong Kong on May 23. PHOTO: MIRXES The 18A rules recognise these start-ups' potential for growth, granting them access to capital as long as they have one core product past the concept phase, HK$1.5 billion in expected market value, and two years of financial records, among other criteria. In Asia, biotech start-ups that have yet to bring in revenue can also choose to list on subsidiary boards that cater to such firms, like China's ChiNext, Singapore's Catalist and Korea's Kosdaq. But the drawbacks include lower trading volumes and hence lower funding , and less visibility . Rebuilding ties in China HKEX's listing reforms, like Chapter 18A, have over the years opened new pathways for a broader range of companies around the world to raise funds in the city. It is on track to be the world's top IPO destination by the end of 2025, according to Swiss investment bank UBS. Its IPO market has raised HK$76 billion so far in 2025, more than seven times that in the same period a year ago, Financial Secretary Paul Chan said on May 25. The city is further cementing its status as a leading fund-raising hub for the tech and biotech sectors. In early May, it set up a scheme to streamline the IPO process for such firms, offering them 'a more efficient pathway' to listing and allowing them to file confidentially to avoid drawing competitors' attention. But some companies seeking a Hong Kong listing may still face a lengthy approval process from the China Securities Regulatory Commission, under rules introduced in March 2023 that also pertain to firms with principal business operations in mainland China. Mirxes, which has laboratories in Hangzhou, filed to list in Hong Kong in July 2023. One of Mirxes' laboratories in Singapore. It has a presence in China, Japan, Malaysia, the Philippines and the United States. PHOTO: MIRXES Dr Zhou said that while his China background is 'definitely helpful' in bringing Mirxes to the world's second-biggest economy, 'honestly, I had to rebuild all my connections there as I had left China as a secondary school student'. These days, he is a 'weekend dad', travelling around mainland China, Hong Kong and South-east Asia for work and seeing his family in Singapore only on weekends. 'Most people – my parents included – will not be able to fully comprehend the technical details of what we do at Mirxes,' Dr Zhou said. The firm will allocate some of its IPO funds to promote awareness and the use of GastroClear in China and South-east Asia. The cash will also fund ongoing research into its colorectal and multi-cancer detection tests, among other plans. Reflecting on Mirxes' journey from fledgling start-up to IPO, Dr Zhou said the listing 'would not have been possible without the Singapore Government's strong support and consistent investment in life sciences over the years'. 'It proves a point that our Singapore technologies and companies are as good, if not better, than others,' he said. 'But we tend to be a little too humble, and not as patient .' The vibrant ecosystem of biotech firms in Boston or San Francisco, for example, was built up over 50 years, the CEO noted. 'In Singapore, we started only some 20 years ago … We are reaching a point where we should see more companies like Mirxes taking their next steps .' Dr Zhou hopes Mirxes' IPO will go a long way in enhancing the company's global credibility. 'If the public sees that this biotech firm has been vetted, has gone public, and everything about it is transparent and fully disclosed, that will add a layer of trust,' he said. 'And in the healthcare business, trust is very important.' Magdalene Fung is The Straits Times' Hong Kong correspondent. She is a Singaporean who has spent about a decade living and working in Hong Kong. Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
3 days ago
- Straits Times
French multinational Thales to launch AI centre in Singapore
Minister for Digital Development and Information Josephine Teo speaks at the France-Singapore Frontier Technologies Forum 2025 on May 30. ST PHOTO: KEVIN LIM SINGAPORE – French aerospace and defence giant Thales will set up a new artificial intelligence (AI) centre in Singapore to develop AI solutions for critical environments and strengthen its research and development capabilities. Solutions that are developed at the cortAIx (pronounced 'cortex') centre will benefit the company's global network, said Minister for Digital Development and Information Josephine Teo at the France-Singapore Frontier Technologies Forum, held at the Fullerton Hotel on May 30. The Singapore centre will be Thales' fourth cortAIx site, after France, Canada and Britain, said Thales cortAIx factory vice-president Mickael Brossard. Launched in 2024, cortAIx is an initiative by the French firm to accelerate the development of artificial intelligence for aircraft, armed forces and critical infrastructure, bringing together experts in the sector. Thales, which has operated in Singapore since 1973 and currently conducts manufacturing and maintenance here, among other activities , also signed a deal with the Civil Aviation Authority of Singapore on May 30 to set up an International Avionics Lab here in 2026, to develop and test new solutions for air traffic management and airport operations. These agreements were among several between French and local organisations that were unveiled at the forum. Mrs Teo announced that France's National Centre for Scientific Research, through its centre at the National University of Singapore's Create facility, will participate in Singapore's National Robotics Programme to strengthen research in embodied AI. Embodied AI is the integration of artificial intelligence with physical systems. The collaboration will be supported with funding of $20 million, Mrs Teo said. (From left) Mistral AI VP Revenue Geoff Soon, cortAIx Factory VP Mickael Brossard, CNRS CEO and President Antoine Petit, HTC Assistant Chief Executive, Chief AI Officer Ang Chee Wee, ST Engineering Group CTO Lee Shiang Long and AI Singapore AI Innovation director Laurence Liew during a panel discussion at the France-Singapore Frontier Technologies Forum 2025 on May 30. ST PHOTO: KEVIN LIM Meanwhile, French start-up Mistral AI will partner with ST Engineering on applied AI engineering, she added. This comes on top of a tie-up between Mistral AI, the Home Team Science and Technology Agency (HTX) and Microsoft to enhance Home Team operations, announced on May 26. In January, the start-up said it had plans to set up a Singapore office. Mrs Teo also announced that aerospace giant Airbus will work with Singapore's Economic Development Board and the Infocomm Media Development Authority to jointly develop potential applications for a 5G-non-terrestrial network, in which satellites and other high-altitude platforms are used to extend 5G coverage and functionality. 'They aim to reduce time lag and quicken responsiveness of AI systems, so they can be deployed in more scenarios,' she said. French energy company Engie will also partner with transport operator SBS Transit on reducing the carbon footprint of public transport, Mrs Teo said. Singapore and France are both strong proponents of multilateralism, she said. 'Our world is becoming more fractious and unpredictable. Yet, Singapore and France have continued to support an open and inclusive trading system,' she said. 'While tariff-induced uncertainties persist, French businesses operating in Singapore can continue to benefit from the Asean Free Trade Area, which makes it more cost-effective for French businesses in Singapore to export and source goods from this region,' said Mrs Teo. Minister for Digital Development and Information Josephine Teo, National Robotics Programme Executive Director (Designate) Tung Meng Fai, CNRS CEO and President Antoine Petit, and French Minister Delegate for Artificial Intelligence and Digital Affairs Clara Chappaz at the bilateral agreement presentation on May 30. ST PHOTO: KEVIN LIM Ms Clara Chappaz, France's Minister Delegate for artificial intelligence and digital technologies, said the two countries had a common mission not only to see technology develop, but to see it used for the common good. Speaking at the event, Minister-in-charge of Energy, and Science and Technology Tan See Leng noted that ties between the two countries were 'underpinned by strong economic cooperation that has grown steadily over the years'. Manpower Minister and Minister in charge of Energy and Science and Technology Tan See Leng speaking at the France-Singapore Frontier Technologies Forum 2025 on May 30. ST PHOTO: KEVIN LIM France is currently the Republic's second-largest goods trading partner and third-largest investor among EU member states, Dr Tan said, adding that more than 2,600 French firms operate here. 'Since the EU-Singapore Free Trade Agreement (EUSFTA) entered into force in 2019, bilateral goods trade has grown by around 10 per cent to exceed $21 billion in 2024. Bilateral services trade also expanded by around 20 per cent to surpass $8 billion in 2023,' he said. The announcements were made in conjunction with a state visit by French President Emmanuel Macron to Singapore. Prime Minister Lawrence Wong had earlier announced the two countries would upgrade their bilateral ties to a Comprehensive Strategic Partnership, which would deepen cooperation in existing sectors as well expand collaboration in new areas such as decarbonisation. Join ST's WhatsApp Channel and get the latest news and must-reads.
Straits Times
4 days ago
- Straits Times
Fast Lane: New Toyota RAV4 here in 2026, ride in Kia EV5 on a rooftop track
Hot SUV: The new Toyota RAV4 is expected to arrive in Singapore in 2026. PHOTO: TOYOTA Fast Lane: New Toyota RAV4 here in 2026, ride in Kia EV5 on a rooftop track Toyota RAV4 in 2026 The latest Toyota RAV4 was unveiled on May 21 and the car is going to be in Singapore in 2026. This is the first time that the mid-sized sport utility vehicle (SUV) is available in the GR Sport trim. Besides having a more sporty-looking bodykit over the Core and Adventure versions of the RAV4, the GR Sport has a 20mm wider wheel track, performance suspension dampers, strengthened rear suspension brace and a specifically tuned steering system. All three versions have slightly different front-end and wheel arch moulding design. The interior looks more rugged than the current-generation RAV4, which has been on sale in Singapore since 2019 and facelifted in 2022. With the rear seats in use, the new car has a boot capacity of 749 litres, up from 733 litres before. The car will also have Toyota's new multimedia system, which is more customisable and responsive than earlier versions. In terms of powertrain, a new plug-in hybrid system with an electric driving range of 150km and an improved hybrid system were mentioned. A spokeswoman for Borneo Motors, Toyota's Singapore distributor, said the new car will 'most likely' be launched here in 2026, although pricing and the variants available for Singapore are yet to be confirmed. Book a ride on a rooftop in the Kia EV5 Joyrider: From early June, the Kia EV5 will take on the banked Skytrack on the rooftop of the Hyundai plant in Bulim Avenue. ST PHOTO: GAVIN FOO From early June, the Kia EV5 electric sport utility vehicle will be used to give passenger rides on the 620m-long Skytrack on the rooftop of the Hyundai Motor Group Innovation Center Singapore at the Jurong Innovation District. The banked track is otherwise used for final quality checks on new electric vehicles before they are handed over to their owners. The passenger ride is free, but must be booked in advance. For details , go to The EV5 is the first Kia electric vehicle to be assembled at the Hyundai-owned plant in Bulim Avenue. Three versions were announced on May 28 – the 400km-range Air that uses a 100kW motor; Earth, which is just as powerful but has a longer 540km range; and the GT Line, a 230kW dual-motor EV that is said to be able to travel 470km on a full charge. The new EV5 is now at the Kia showroom at 239 Alexandra Road and is priced from $194,000 with certificate of entitlement (COE). Customised-in-Bali motorcycle at London show Indo-mean: The aggressively styled Phoenix motorcycle is the creation of a workshop in Bali, Indonesia. PHOTO: ROYAL ENFIELD Royal Enfield presented seven modified motorcycles at the Bike Shed Moto Show London 2025 held from May 23 to 25. Among them was the Phoenix, which was the creation of Mr Putu Ajus Mulyawarman, owner of AMS Garage in Bali, Indonesia. The dramatic Phoenix is based on a Royal Enfield Super Meteor 650 with low-riding, 'tribal style' bodywork that is made from exposed aluminium. Royal Enfield is one of the oldest motorcycle brands, having been in operation since 1901. In 1994, it was sold to multinational automotive company Eicher Motors . Today, it is active in 60 countries, including Singapore. Right-hand-drive Vietnamese EV Primed for export: The launch of the right-hand-drive version VinFast VF6 in Indonesia opens the possibility for the EV brand to come to Singapore. PHOTO: VINFAST VinFast Auto, the carmaker under Vietnam's Vingroup, unveiled the right-hand-drive version of its VF6 in Indonesia. This is an electric SUV that rivals the BYD Atto 3 in size and paves the way for the brand to be introduced in other right-hand-drive countries in the region, including Singapore. The VF6 Eco is powered by a single 130kW motor and is said to be able to travel up to 480km on a full-charge under the New European Driving Cycle test procedure, which is more optimistic than the Worldwide Harmonized Light Vehicles Test Procedure standard adopted by Singapore. The higher-grade VF6 Plus has a 150kW motor and an operating range of 460km. In Indonesia, the car comes with free charging until March 1, 2028, at VinFast-operated stations. VinFast's chief executive and founder Pham Nhat Vuong told shareholders in April that due to high logistics fees in North America and Europe, the company is pushing expansion into Asian markets instead. Chinese carmakers questioned over 'zero-mileage' used cars The Chinese government is looking into the increasing number of used cars on sale that have never been driven, according to a Reuters report. This comes after Mr Wei Jianjun, chairman of Great Wall Motor, said in a separate report that the industry's years-long price war has caused the emergence of 'second-hand cars with zero mileage' in the Chinese market. An unnamed source in the Reuters article said carmakers and dealers were potentially doing this to meet aggressive sales targets. It is possible to find pre-owned cars with hardly any mileage on sale in Singapore. While there are no rules against this practice here, industry insiders opined that pre-registering cars without actual buyers artificially inflates demand for COEs. Monster Jam tickets selling fast Motor mania: Monster trucks will be performing stunts at the National Stadium on Aug 23. PHOTO: MONSTER JAM Tickets to catch trucks weighing more than five tonnes performing stunts at the National Stadium on Aug 23 are said to be selling fast. The show begins at 6pm, while the Pit Party, where ticket holders can get close to the vehicles, happens from 1 to 4pm. The tickets are priced from $25 and are available through Join ST's Telegram channel and get the latest breaking news delivered to you.
